RxDoctor Payments Data

John Vasil, DO

Family Medicine · Northern Cambria, PANPI 1629089982

Payments from drug & device makers

$8,589in general payments, 2019–2025

Across 563 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$748
  • Amarin Pharma, Inc.$554
  • GSK$464
  • Boehringer Ingelheim$356
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,54699%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,589 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,956
Medicare patients
96
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide129$155,902
OzempicSemaglutide115$111,462
JardianceEmpagliflozin108$91,830
EliquisApixaban82$60,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$58,625
FarxigaDapagliflozin Propanediol73$55,565
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl367$43,129
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$28,352
TrulicityDulaglutide27$26,561
CreonLipase/Protease/Amylase11$23,616
TradjentaLinagliptin27$21,478
SublocadeBuprenorphine11$21,306
BrixadiBuprenorphine12$19,456
VivitrolNaltrexone Microspheres12$17,725
XareltoRivaroxaban12$17,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,728$267,365244 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat, Stiolto Respimat$356$133,122171 claims
GSKTrelegy Ellipta, Breo Ellipta$464$74,056104 claims
AstraZenecaFarxiga$1,261$55,56573 claims
AbbVieCreon, Vraylar$748$38,50822 claims
Lilly USA, LLCTrulicity$161$26,56127 claims
Indivior Inc.Sublocade$259$21,30611 claims
Braeburn Inc.Brixadi$179$19,45612 claims
Johnson & JohnsonXarelto$212$17,44612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Northern Cambria

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →